More From The Market Online
Mesoblast back to record highs as Ryoncil sales jump 60% QoQ to US$35M
Mesoblast is back onto investors' radars with good tidings from its sale of Ryoncil, with that…
- Jonathon Davidson
- 2 mins
- 09 January 2026 14:30 (AEDT)
4DX up another 15% on new demo delivery; now boasting $2.5B cap & no revenue
4DMedical has climbed to a lofty valuation just short of $4.80 on Wednesday, bringing the biotech…
- Jonathon Davidson
- 2 mins
- 07 January 2026 12:07 (AEDT)
Paradigm Biopharma rolls into CY26 on patient tailwinds after hitting 25% recruitment milestone
Late-stage drug developer Paradigm Biopharmaceuticals is preparing for a huge CY26 after landing a key recruitment…
- Isaac McIntyre
- 2 mins
- 05 January 2026 10:25 (AEDT)
Listen: From the Wire – Paradigm Biopharma CEO and Founder Paul Rennie
From The Wire: Senior markets reporter Jonathon Davidson sat down with Paradigm Biopharmaceuticals chief executive officer…
- Jonathon Davidson
- 2 mins
- 10 December 2025 16:42 (AEDT)
